Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDI7SVJX5E)
  Drug Name Carbidopa Drug Info Oxitriptan Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antiparkinson Agents Antidepressants
  Structure

 Mechanism of Carbidopa-Oxitriptan Interaction (Severity Level: Moderate)
     Additive dopaminergic effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Carbidopa Oxitriptan
      Mechanism Dopaminergic effects
Aromatic-L-amino-acid decarboxylase  Inhibitor 		Dopaminergic effects
Dopamine receptor  Agonist
      Key Mechanism Factor 1
Factor Name Aromatic-L-amino-acid decarboxylase
×
Structure Sequence
MNASEFRRRGKEMVDYMANYMEGIEGRQVYPDVEPGYLRPLIPAAAPQEPDTFEDIINDVEKIIMPGVTHWHSPYFFAYFPTASSYPAMLADMLCGAIGCIGFSWAASPACTELETVMMDWLGKMLELPKAFLNEKAGEGGGVIQGSASEATLVALLAARTKVIHRLQAASPELTQAAIMEKLVAYSSDQAHSSVERAGLIGGVKLKAIPSDGNFAMRASALQEALERDKAAGLIPFFMVATLGTTTCCSFDNLLEVGPICNKEDIWLHVDAAYAGSAFICPEFRHLLNGVEFADSFNFNPHKWLLVNFDCSAMWVKKRTDLTGAFRLDPTYLKHSHQDSGLITDYRHWQIPLGRRFRSLKMWFVFRMYGVKGLQAYIRKHVQLSHEFESLVRQDPRFEICVEVILGLVCFRLKGSNKVNEALLQRINSAKKIHLVPCHLRDKFVLRFAICSRTVESAHVQRAWEHIKELAADVLRAERE
Gene Name DDC
Uniprot ID DDC_HUMAN
KEGG Pathway hsa:1644
Protein Family Group II decarboxylase family
Protein Function
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine and L-5-hydroxytryptophan to serotonin.
    Click to Show/Hide
      Key Mechanism Factor 2
Factor Name Dopamine receptor Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
    Click to Show/Hide
      Mechanism Description
  • Additive dopaminergic effects by the combination of Carbidopa and Oxitriptan 

Recommended Action
      Management In general, 5-hydroxytryptophan should not be given with carbidopa. If the combination is used, close monitoring is recommended for signs and symptoms of excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia.

References
1 Hardman JG, Limbird LE, Gilman AG, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed." New York, NY: McGraw-Hill (2001):.
2 Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK "Development of a scleroderma-like illness during therapy with L-5- hydroxytryptophan and carbidopa." N Engl J Med 303 (1980): 782-7. [PMID: 6997735]
3 Magnussen I, Van Woert MH "Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors." Eur J Clin Pharmacol 23 (1982): 81-6. [PMID: 6182005]